TCGX Acquisition Corp. II
Searching since IPO 2026-10-16- CIK 2149916
- TCXB
- IPO 2026-10-16
- 15 filings
- IPO Size
- $100M
- raised at the IPO
- Current Status
- IPO
- from its latest filing
- IPO Year
- 2026
- year it listed
Filings, by quarter
15 filings over 2 quarters; violet bars carry a milestone
- 26 Q3: 1 filing
- 26 Q4: 14 filings
- S-1 filed 26 Q3
- IPO 26 Q4
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
TCGX Acquisition Corp. II is a blank-check company seeking an initial business combination, with a focus on healthcare, life sciences and medical technology companies. Its search may include Asia and China, with China-sourced assets expected to be a primary focus.
Investment Focus
Healthcare, Biopharmaceuticals, Technology
Geographic Focus
Asia, China
Key Information
As the filings state it
- IPO Date
- 2026-10-16
- Jurisdiction of Incorporation
- Cayman Islands
- SPAC Ticker
- TCXB
Stock Performance
TCXBTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2026-10-16 | $11.20 | |
| Current Price | 2026-10-23 | $10.49 | -6% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The team is led by Chen Yu, founder of TCGX and an experienced healthcare investor and operator, and Craig Skaling, an experienced finance and alternative-asset-management executive. Its independent director nominees bring biotechnology company-building, drug-development, healthcare operating and investment experience.